

### **Contents**

# Volume 43 Issue 2 | February 2017

#### Introduction

**(3)** 

The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an OPEN ACCESS introduction NEyal

## **Background**

Why cure, why now? DR Kuritzkes 67

**(3)** 

Improving on effective antiretroviral therapy: 71 how good will a cure have to be? K A Freedberg, OPEN ACCESS PESax

74 How to keep high-risk studies ethical: classifying candidate solutions N Eyal **(a)** 

### **Risks**

78 First-in-human HIV-remission studies: reducing and justifying risk R Dresser

When to start paediatric testing of the adult HIV 82 **(3)** cure research agenda? S K Shah

87 Risk and radical uncertainty in HIV research **(a)** C Hare OPEN ACCESS

# **Benefits to participants**

Why high-risk, non-expected-utility-maximising gambles can be rational and beneficial: the case of HIV cure studies L Buchak

96 For love and money: the need to rethink benefits in HIV cure studies E Largent

**100** An activist's argument that participant values



should guide risk—benefit ratio calculations in OPEN ACCESS HIV cure research D Evans

### Informed consent

**104** Cure research and consent: the Mississippi Baby, Barney Clark, Baby Fae and Martin Delaney G I Annas

Informed consent to HIV cure research D Bromwich, I R Millum

## **Benefits to nonparticipants**

114 Must research benefit human subjects if it is to **(3)** be permissible? D Wikler

118 The social value of candidate HIV cures:

**(a)** actualism versus possibilism R Brown, N G Evans

124 Contractualist reasoning, HIV cure clinical trials, and the moral (ir)relevance of the risk/benefit open access ratio R Kumar

The morality of risks in research: reflections on Kumar F M Kamm

### Afterword

**132** Afterword: returning to philosophical foundations in research ethics N Eval



This article has been chosen by the editor to be of special interest or importance and is freely available online.



This article has been made freely available Online under the BMJ Journals Open Access scheme. See http://jme.bmj.com/ site/about/guidelines.xhtml#open



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics www.publicationethics.org/



